QV Bioelectronics Receives £1.26M Grant for Brain Cancer Treatment Development
Deal News | May 07, 2025 | Catapult Ventures Group
QV Bioelectronics, under the support of Catapult Ventures Group, has been awarded £1.26 million through the Biomedical Catalyst programme to advance its research on an implanted Electric Field Therapy (EFT) device, GRACE, for treating brain tumours. Designed for continuous, targeted therapy, GRACE has shown promising results in preclinical studies, aiming to improve treatment for glioblastoma—an aggressive brain cancer with poor prognosis. The funding will facilitate key technical and regulatory milestones, including preparatory steps for a first-in-human trial, further safety testing, and engagement with the MHRA and NHS. QV Bioelectronics has secured over £3 million in grant funding and an equivalent in equity investment to support its mission of pioneering implantable bioelectronics in oncology. Prominent figures including Dr. Christopher Bullock and Professor Paul Brennan have expressed optimism about GRACE's potential impact on patient outcomes.
Sectors
- Biomedical Research
- Healthcare & Medical Devices
Geography
- United Kingdom – QV Bioelectronics is based in the UK, and the funding comes from the Biomedical Catalyst programme, a UK government initiative.
Industry
- Biomedical Research – The development and preclinical testing of innovative biomedical devices for cancer treatment, specifically Electric Field Therapy devices.
- Healthcare & Medical Devices – QV Bioelectronics' work on implantable devices for brain tumours represents cutting-edge medical device innovation within the healthcare sector.
Financials
- £1.26M – Biomedical Catalyst programme grant awarded to QV Bioelectronics for developing the GRACE device.
- £3M – Total grant funding secured by QV Bioelectronics for its initiatives.
- £3M – Equity investment secured by QV Bioelectronics.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| QV Bioelectronics | Developer of the GRACE device | Company | A company pioneering implantable bioelectronics to improve cancer treatment outcomes. |
| Catapult Ventures Group | Supporting investor | Company | A private equity firm providing investment to QV Bioelectronics for its innovative medical device. |
| Biomedical Catalyst | Grant provider | Government | A catalytic funding programme by Innovate UK to support innovative research and development in life sciences. |
| Dr. Christopher Bullock | CEO of QV Bioelectronics | Person | Leads QV Bioelectronics in developing new medical technologies. |
| Paul Brennan | Consultant and contributor | Person | Honorary Consultant Neurosurgeon and Clinical Director of Neurosurgery at the University of Edinburgh; supports the development of GRACE. |